Separate terms with OR to return results that match either term.
 
Clear All

611 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name (Ascending) Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9204 Mogamulizumab-kpkc Poteligeo 1mg Immunotherapy Monoclonal Antibody CCR4 No 2018 Oct. 1, 2019 In Use
J9313 Moxetumomab-pasudotox-tdfk Lumoxiti 0.01mg Immunotherapy Drug Antibody Conjugate CD22 No 2018 Oct. 1, 2019 In Use
J8650 Nabilone Cesamet 1 mg Ancillary Therapy Antiemetic Cannabinoid Yes 1985 Jan. 1, 2007 In Use
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use
J9348 Naxitamab Danyelva 1mg Immunotherapy Monoclonal Antibody GD2 No 2020 July 23, 2021 In Use
C9475 Necitumumab Portrazza 1 mg Immunotherapy Monoclonal Antibody EGFR No 2015 April 1, 2016 In Use
J9295 Necitumumab Portrazza 1 mg Immunotherapy Monoclonal Antibody EGFR No 2015 Jan. 1, 2017 In Use
J9261 Nelarabine Arranon 50 mg Chemotherapy Antimetabolite Purine Analog No 2005 Jan. 1, 2007 In Use
NA Neratinib Nerlynx 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2017 In Use
J8655 Netupitant/palonostron Akynzeo 300mg/0.5 mg Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Yes 2014 Jan. 1, 2016 In Use

Found 611 results in 3 millisecondsExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.